PD-1 inhibitor therapy causes multisystem immune adverse reactions: a case report and literature review
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.961266
Abstract: Immune checkpoint inhibitors(ICIs), including cytotoxic T-lymphocyte antigen 4 (anti-CTLA-4), programmed cell death protein 1 and its ligand (PD-1/PD-L1) inhibitors, have been shown to have antitumor activity in various solid tumors. Their mechanism of action is… read more here.
Keywords: causes multisystem; therapy; multisystem immune; therapy causes ... See more keywords